本报告仅为参考之用，在任何地区均不应被视为买卖任何证券、金融工具的要约或要约邀请。本报告提及的任何证券或金融工具均可能含有重大的风险，可能 不易变卖以及不适合所有投资者。本报告所提及的证券或金融工具的价格、价值及收益可能会受汇率影响而波动。过往的业绩并不能代表未来的表现。 客户应当考虑到国金证券存在可能影响本报告客观性的利益冲突，而不应视本报告为作出投资决策的唯一因素。证券研究报告是用于服务具备专业知识的投资 者和投资顾问的专业产品，使用时必须经专业人士进行解读。国金证券建议获取报告人员应考虑本报告的任何意见或建议是否符合其特定状况，以及（若有必要） 咨询独立投资顾问。报告本身、报告中的信息或所表达意见也不构成投资、法律、会计或税务的最终操作建议，国金证券不就报告中的内容对最终操作建议做出任 何担保，在任何时候均不构成对任何人的个人推荐。 在法律允许的情况下，国金证券的关联机构可能会持有报告中涉及的公司所发行的证券并进行交易，并可能为这些公司正在提供或争取提供多种金融服务。 本报告并非意图发送、发布给在当地法律或监管规则下不允许向其发送、发布该研究报告的人员。国金证券并不因收件人收到本报告而视其为国金证券的客 ...

公 司 报 告 2024 年 04 月 23 日 证 券 研 究 报 告 苑东生物(688513.SH) 事项： | --- | --- | |----------------------------|---------------------| | | | | 主要数据 | | | 行业 | 医药 | | 公司网址 | www.eastonpharma.cn | | 大股东 / 持股 | 王颖 /34.89% | | 实际控制人 | 王颖 | | 总股本 ( 百万股 ) | 120 | | 流通 A 股 ( 百万股 ) | 120 | | | | | 流通 B/H 股 ( 百万股 ) | | | 总市值（亿元） | 72 | | 流通 A 股市值 ( 亿元 ) | 72 | | 每股净资产 ( 元 ) | 21.87 | | 资产负债率 (%) | 22.2 | | 行情走势图 | | 【平安证券】苑东生物（688513.SH）*深度报告*聚焦 麻醉镇痛创新管线，纳美芬海外市场放量可期* 推荐 20231220 【平安证券】苑东生物（688513.SH）*季报点评*前三 季度利润 端压 力趋缓 ，制剂 国际 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-022 成都苑东生物制药股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2024年4月22日召开第 三届董事会第十七次会议及第三届监事会第十三次会议审议通过了《关于使用闲置 自有资金进行现金管理的议案》，同意公司及下属子公司自公司董事会审议通过之 日起18个月内使用不超过人民币15亿元的闲置自有资金进行现金管理，产品期限不 超过15个月，产品风险等级为低风险（对应金融机构内部评级为R1、PR1或其他等 同于低风险的评级级别）、中低风险（对应金融机构内部评级为R2、PR2或其他等 同于中低风险的评级级别），其中购买中低风险的非保本理财产品额度不得超过3 亿元。董事会授权总经理行使该项决策权及签署相关法律文件，具体事项由公司财 务部负责组织实施。本事项属于公司董事会决策权限范围内，无需提交公司股东大 会审议。现将相关情况公告如下： 一、本次使用闲置自有资金进行 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-021 成都苑东生物制药股份有限公司 关于开展票据池业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）于 2024 年 4 月 22 日召 开第三届董事会第十七次会议及第三届监事会第十三次会议，审议通过了《关于 开展票据池业务的议案》，同意公司及下属子公司与金融机构开展不超过人民币 10,000 万元额度的票据池业务，即与国内商业银行合作开展票据池业务即期余额 不超过人民币 10,000 万元，有效期 18 个月，业务期限内该额度可滚动使用。现 将相关情况公告如下： （三）业务期限 上述票据池业务的开展期限为自董事会审议通过之日起 18 个月内。 （四）实施额度 公司及子公司共享不超过 10,000 万元的票据池额度，即用于与所有合作银 行开展票据池业务的质押的票据累计即期余额不超过人民币 10,000 万元，业务 期限内，该额度可滚动使用。 （五）担保方式 1 一、情况概述 （一）业务概述 票据池业务 ...

成都苑东生物制药股份有限公司 2023 年度审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879900 www.zhcpa.cn 否由具有技业许可 您可使用手机"扫一扫"或进入 审计报告 中汇会审[2024]3569号 成都苑东生物制药股份有限公司全体股东: 一、审计意见 我们审计了成都苑东生物制药股份有限公司(以下简称苑东生物公司)财务报 表,包括2023年12月31日的合并及母公司资产负债表,2023年度的合并及母公司 利润表、合并及母公司现金流量表、合并及母公司所有者权益变动表以及财务报 表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制, 公允反映了苑东生物公司2023年12月31日的合并及母公司财务状况以及2023年度 的合并及母公司经营成果和现金流量。 二、形成审计意见的基础 我们按 ...

证券代码：688513 证券简称：苑东生物 公告编号：2024-017 成都苑东生物制药股份有限公司 第三届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 成都苑东生物制药股份有限公司（以下称"公司"）第三届董事会第十七次会 议于 2024 年 4 月 22 日以现场和通讯相结合的方式召开。会议通知已于 2024 年 4 月 12 日以专人送达、电话通知、电子邮件等形式送达全体董事。本次会议由 董事长王颖主持，应出席董事 9 名，实际出席董事 9 名。本次会议的召集、召开 和表决程序符合《中华人民共和国公司法》等相关法规和《成都苑东生物制药股 份有限公司章程》的规定，会议形成的决议合法有效。 二、董事会会议审议情况 经与会董事审议，逐项表决，形成决议如下： （一）审议通过《关于<公司 2023 年度总经理工作报告>的议案》 公司总经理袁明旭先生对公司 2023 年度经营情况、2024 年的经营计划等事 项向董事会做了汇报。 表决结果：9 票赞成，0 票反对，0 票弃权。同 ...

成都苑东生物制药股份有限公司 董事会对会计师事务所履职情况评估报告 成都苑东生物制药股份有限公司（以下简称公司）聘请中汇会计师事务所（特 殊普通合伙）（以下简称"中汇会计师事务所"）作为公司 2023 年度年报审计师。 根据财政部、国资委及证监会颁布的《国有企业、上市公司选聘会计师事务 所管理办法》，公司对中汇会计师事务所在近一年审计中的履职情况进行了评估。 经评估，公司认为，近一年中汇会计师事务所资质等方面合规有效，履职能够保 持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、资质条件 （一）事务所基本信息 中汇会计师事务所，于 2013 年 12 月转制为特殊普通合伙，管理总部设立于 杭州，系原具有证券、期货业务审计资格的会计师事务所之一，长期从事证券服 务业务。 事务所名称：中汇会计师事务所（特殊普通合伙） 成立日期：2013 年 12 月 19 日 组织形式：特殊普通合伙 注册地址：杭州市江干区新业路 8 号华联时代大厦 A 幢 601 室 首席合伙人：余强 上年度末（2023 年 12 月 31 日）合伙人数量：103 人 上年度末（2023 年 12 月 31 日）注册会计师人数：701 人 ...

acks III EASTON BIOPHARMACEUTICALS 19 "提质增效重回报"行动方案 2024年度 股票代码 | 688513 EASTON BIOPHARMACEUTICALS 为践行"以投资者为本"的上市公司发展理念，推动上市公司持续优化经营、规范治 理和积极回报投资者，大力提高上市公司质量，成都苑东生物制药股份有限公司（ 以下简称"苑东生物"或"公司"）基于对未来发展前景的信心及价值的认可，特此制 定苑东生物2024年度"提质增效重回报"行动方案。 2024年，公司将积极采取措施，开展"提质增效重回报"专项行动，加大技术创新 的投入，加强内控管理，提高公司经营质量，以进一步巩固公司行业领先地位、提 升核心竞争力。同时，公司将强化管理层与股东利益共担共享，增强投资者回报和 获得感，保障投资者权益，树立良好的资本市场品牌形象。 the start of the ANT (1995) 1172 lid. Prop 2 - 2 - 2 持续保持高研发投入 锻造创新驱动发展引擎 苑东生物始终坚持"以患者为中心，为人类健康沐浴阳光"的企业使命，秉承" 阳光、价值、创新、高效"的价值观，以"成就自我 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥314,990,089.28, representing a year-on-year increase of 13.37%[3] - The net profit attributable to shareholders for the same period was ¥75,010,084.96, reflecting a growth of 23.00% compared to the previous year[3] - Operating profit for Q1 2024 was ¥80,220,974.65, up 17.5% from ¥68,278,212.94 in Q1 2023[19] - Net profit for Q1 2024 was ¥75,010,084.96, representing a 22.1% increase from ¥60,985,871.41 in Q1 2023[19] - Earnings per share for Q1 2024 were ¥0.63, compared to ¥0.51 in Q1 2023, reflecting a growth of 23.5%[20] - The total operating costs for Q1 2024 were ¥258,240,843.28, an increase of 14.0% from ¥226,451,481.30 in Q1 2023[18] Cash Flow - The net cash flow from operating activities increased significantly by 118.29%, amounting to ¥71,892,080.50[3][8] - Cash flow from operating activities for Q1 2024 was ¥71,892,080.50, significantly higher than ¥32,933,694.58 in Q1 2023[22] - The net cash flow from financing activities was -$63,998,569.10, indicating a significant outflow compared to the previous period's inflow of $49,320,319.44[23] - Total cash and cash equivalents at the end of the period amounted to $816,632,829.91, an increase from $767,540,657.11 at the beginning of the period[23] - Cash outflows from financing activities totaled $113,998,569.10, which included $60,000,000.00 for debt repayment and $1,281,279.84 for dividend payments[23] - The impact of exchange rate fluctuations on cash and cash equivalents was a decrease of $97,939.72[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,374,370,944.83, showing a slight increase of 0.83% from the end of the previous year[4] - As of March 31, 2024, total assets amounted to RMB 3,374,370,944.83, an increase from RMB 3,346,754,293.88 as of December 31, 2023, reflecting a growth of approximately 0.82%[16] - Total current liabilities were RMB 666,671,871.78, slightly up from RMB 661,094,015.47, showing an increase of approximately 0.87%[16] - The total liabilities amounted to RMB 748,260,937.50, up from RMB 743,334,130.15, indicating an increase of about 0.81%[16] - Non-current assets totaled RMB 1,470,683,597.65, a slight increase from RMB 1,463,883,064.24, reflecting a growth of approximately 0.14%[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 3,619[10] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[12] Research and Development - Research and development expenses totaled ¥63,140,560.59, which is 20.05% of the operating revenue, an increase of 1.57 percentage points year-on-year[4] - Research and development expenses for Q1 2024 totaled ¥54,184,914.96, an increase from ¥50,088,561.76 in Q1 2023[19] Other Information - The company reported non-recurring gains of ¥22,918,205.83 for the quarter[7] - The weighted average return on equity was 2.87%, an increase of 0.41 percentage points compared to the previous year[3] - The total equity attributable to shareholders was ¥2,626,110,007.33, up by 0.87% from the previous year-end[4] - The company reported a total equity attributable to shareholders of ¥2,626,110,007.33, up from ¥2,603,420,163.73 in Q1 2023[17] - There were no new strategies or product developments mentioned in the conference call[13] - The company did not apply new accounting standards or interpretations for the first quarter of 2024[23]

Financial Performance - The company's operating revenue for 2023 was CNY 1,117,120,749.58, a decrease of 4.56% compared to CNY 1,170,512,900.63 in 2022 [22]. - The net profit attributable to shareholders for 2023 was CNY 226,574,420.57, down 8.09% from CNY 246,520,758.07 in 2022 [22]. - The net cash flow from operating activities increased by 81.15% to CNY 275,252,239.23 in 2023, compared to CNY 151,944,665.50 in 2022 [23]. - The total assets at the end of 2023 were CNY 3,346,754,293.88, reflecting a 10.91% increase from CNY 3,017,540,233.11 at the end of 2022 [23]. - The company's net assets attributable to shareholders increased by 6.50% to CNY 2,603,420,163.73 at the end of 2023, compared to CNY 2,444,459,716.15 at the end of 2022 [23]. - The basic earnings per share for 2023 were CNY 1.89, a decrease of 7.80% from CNY 2.05 in 2022 [24]. - The company's operating revenue for the reporting period was CNY 1,117.12 million, a decrease of 4.56% compared to CNY 1,170.51 million in the same period last year [135]. - The net profit attributable to shareholders was CNY 226.57 million, down 8.09% year-on-year; net profit excluding non-recurring gains and losses was CNY 157.58 million, a decrease of 4.32% [37]. Research and Development - Research and development expenses accounted for 22.03% of operating revenue in 2023, down from 22.65% in 2022 [24]. - The company has over 10 Class 1 innovative drugs in development, with EP-0108 capsules having received CDE clinical trial approval and EP-0146 tablets' clinical application accepted by CDE [59]. - The company is focusing on a research and development model driven by clinical needs, emphasizing small molecule innovative drugs, biological drugs, and high-end generic drugs [63]. - The company has a specialized R&D team of 442 personnel, including 178 with doctoral degrees, supporting continuous innovation and development [120]. - The company reported a total R&D expenditure of ¥246,087,516.90 in 2023, a decrease of 7.19% compared to ¥265,138,502.04 in the previous year [87]. - The company has applied for 63 new invention patents in 2023, bringing the total number of invention patents to 371, with 107 granted [85]. - The company is currently conducting Phase III clinical trials for one new chemical drug and has initiated Phase Ib/II trials for another biological drug [186]. Product Development and Approvals - The company has received approval for 10 formulation products, including critical drugs, and has a total of 48 high-end formulation products approved for market [42]. - The first internationalized formulation product, Nalmefene Hydrochloride Injection, received FDA approval [42]. - The company has submitted registration for multiple products, including Indobufen tablets with a production value of 1,462.08 million and a market value of 1,189.44 million [100]. - The company is developing a new injectable formulation of Bumetanide, which has a production value of 700.00 million and a market value of 629.82 million, leveraging its experience in injectable products [100]. - The company has submitted applications for several new products, including Nicardipine Hydrochloride Injection and Alprostadil Sodium Tablets, both classified as Class 4 [189]. - The company received approval for the production of multiple products in 2023, including Aripiprazole Oral Solution and Lacosamide Oral Solution, expanding its portfolio in psychiatric and epilepsy treatments [192]. - The company is actively pursuing regulatory approvals for its new products, which are expected to contribute to revenue growth in the coming years [192]. Market and Competitive Position - The company has a strong market presence, with three of its products ranking first in market share, including sodium namifen injection, naloxone injection, and ibuprofen injection [74]. - The company is expanding its international market presence, recently entering Poland and Kazakhstan as part of the Belt and Road Initiative [50]. - The company is focusing on high-quality development in the pharmaceutical industry, with key areas including oncology, cardiovascular diseases, and diabetes [166]. - The company aims to enhance operational efficiency and maintain competitiveness through integrated raw material and formulation strategies amid ongoing centralized procurement policies [169]. - The company is actively pursuing market expansion and product registration to enhance its competitive position in the pharmaceutical industry [104]. Risks and Challenges - The company has detailed various risks and countermeasures in its annual report, which investors should pay attention to [4]. - The company faces risks from national volume-based procurement policies, which could lead to price reductions for its products [123]. - The company received government subsidies amounting to 50.95 million RMB, accounting for 21.09% of total profit, indicating potential future risks if subsidy policies change [132]. - The ongoing reforms in the healthcare system and the promotion of consistent evaluations for generic drugs are enhancing the supply level of generic drugs in China [78]. Corporate Governance and Compliance - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties [9]. - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants [5]. - The company has not disclosed any special arrangements for corporate governance [9]. - The company has implemented a quality management system that has received multiple certifications, including ISO50001 and ISO14001 [47].